When Is a Line Not a Line?

Por Hochster, Howard S.
Publicado em 2007

The Power of “P”: On Overpowered Clinical Trials and “Positive” Results

Por Hochster, Howard S.
Publicado em 2008

Curable Metastatic Colorectal Cancer

Por Hochster, Howard S.
Publicado em 2010

Use of Anti-EGFR Antibodies in First-Line Therapy of Metastatic CRC

Por Hochster, Howard S.
Publicado em 2013

TAS-102: a novel antimetabolite for the 21st century

Por Uboha, Nataliya, Hochster, Howard S
Publicado no Future Oncol (2016)

Rationale for Combining Biotherapy in the Treatment of Advanced Colon Cancer

Por Cohen, Deirdre J., Hochster, Howard S.
Publicado em 2008

Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

Por Zhang, Yue, Hochster, Howard, Stein, Stacey, Lacy, Jill
Publicado no Exp Hematol Oncol (2015)

Section III: Treatment of Advanced Gastrointestinal Cancers

Por Hochster, Howard S., O’Reilly, Eileen M., Ajani, Jaffer A., Venook, Alan P.
Publicado em 2007

A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease

Por Stahl, John M, Walther, Zenta, Chang, Bryan W, Hochster, Howard S, Johung, Kimberly L
Publicado no Cureus (2017)

Tolerance and Activity of Oxaliplatin with Protracted Topotecan Infusion In Patients With Previously Treated Ovarian Cancer. A phase I study

Por Hochster, Howard, Chen, Thomas T., Lu, Janice M., Hills, Day, Sorich, Joan, Escalon, Juliet, Ivy, Percy, Liebes, Leonard, Muggia, Franco
Publicado em 2008

Chronic Thalidomide and Chemoembolization for Hepatocellular Carcinoma

Por Wu, Jennifer, Ng, Jennifer, Christos, Paul J., Goldenberg, Alec S., Sparano, Joseph, Sung, Max W., Hochster, Howard S., Muggia, Franco M.
Publicado no Oncologist (2014)

Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology

Por Marshall, John L., Haller, Daniel G., de Gramont, Aimery, Hochster, Howard S., Lenz, Heinz-Josef, Ajani, Jaffer A., Goldberg, Richard M.
Publicado em 2007

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

Por Kasi, Pashtoon M., Kotani, Daisuke, Cecchini, Michael, Shitara, Kohei, Ohtsu, Atsushi, Ramanathan, Ramesh K., Hochster, Howard S., Grothey, Axel, Yoshino, Takayuki
Publicado no BMC Cancer (2016)

Phase II Study of Paclitaxel plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma

Por Lam, Anthony, Sparano, Joseph A., Vinciguerra, Vincent, Ocean, Allyson J., Christos, Paul, Hochster, Howard, Camacho, Fernando, Goel, Sanjay, Mani, Sridhar, Kaubisch, Andreas
Publicado em 2010

Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG...

Por Hochster, Howard, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Ryan, Theresa, Zhang, Lijun, Colocci, Natalia, Frankel, Stanley, Horning, Sandra J.
Publicado em 2009

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic...

Por Poplin, Elizabeth, Feng, Yang, Berlin, Jordan, Rothenberg, Mace L., Hochster, Howard, Mitchell, Edith, Alberts, Steven, O'Dwyer, Peter, Haller, Daniel, Catalano, Paul, Cella, David, Benson, Al Bowen
Publicado em 2009

A Phase II Study of Oxaliplatin Combined with Continuous Infusion Topotecan for Patients with Previously Treated Ovarian Cancer

Por Stein, Stacey M., Tiersten, Amy, Hochster, Howard S., Blank, Stephanie V., Pothuri, Bhavana, Curtin, John, Shapira, Ilan, Levinson, Benjamin, Ivy, Percy, Joseph, Benson, Guddati, Achuta K., Muggia, Franco
Publicado em 2013

Activity of Topotecan 21-Day Infusion in Patients with Previously Treated Large Cell Lymphoma: Long-term follow-up of an Eastern Cooperative Oncology Group Study (E5493)

Por Wiernik, Peter H., Li, Hailun, Weller, Edie, Hochster, Howard S., Horning, Sandra J., Nazeer, Tipu, Gordon, Leo I., Habermann, Thomas M., Minniti, Carl J., Shapiro, Gary R., Cassileth, Peter A.
Publicado em 2012

A Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody versus Observation following Induction Therapy: A trial of the ECOG-ACRIN Cancer Researc...

Por Barta, Stefan K., Li, Hailun, Hochster, Howard S., Hong, Fangxin, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Colocci, Natalia, Bengtson, Elizabeth M, Horning, Sandra J., Kahl, Brad S.
Publicado no Cancer (2016)

Phase I Study of Bryostatin 1, a Protein Kinase C Modulator, Preceding Cisplatin in Patients with Refractory Non-hematologic Tumors

Por Pavlick, Anna C., Wu, Jennifer, Roberts, John, Rosenthal, Mark A., Hamilton, Anne, Wadler, Scott, Farrell, Kathleen, Carr, Michelle, Fry, David, Murgo, Anthony J., Oratz, Ruth, Hochster, Howard, Liebes, Leonard, Muggia, Franco
Publicado em 2009